Skip to main content

Table 3 Univariate analysis of socio-demography, alcohol drinking, smoking, fruit and vegetable intake, physical activity, and body composition as predictors for pre-diabetes and diabetes at 2 to 3 years post-ART

From: Dysglycemia associations with adipose tissue among HIV-infected patients after 2 years of antiretroviral therapy in Mwanza: a follow-up cross-sectional study

 

PD/DM+a

(n = 61)

PD/DM-b

(n = 212)

Odds Ratio

(95% CI)

P-value

n(%) or mean (sd)

n(%) or mean (sd)

  

Age at follow-up, years

41.8 (7.9)

41.4 (10.3)

1.00 (0.9–1.0)

0.76

Sex

 Male

24 (39.3)

71 (33.5)

Reference

0.40

 Female

37 (60.7)

141 (66.5)

0.78 (0.4, 1.4)

 

Marital status

 Married/cohabiting

26 (42.6)

104 (49.1)

Reference

0.59

 Widow/widower

9 (14.7)

36 (16.9)

1.00 (0.4, 2.3)

 

 Separated/divorced

22 (36.1)

57 (26.9)

1.54 (0.8, 2.9)

 

 Single

4 (6.6)

15 (7.1)

1.07 (0.3, 3.5)

 

Occupation

 Self-employed

51 (83.6)

181 (85.4)

Reference

0.41

 Salaried

3 (5.0)

12 (5.7)

0.89 (0.2, 3.2)

 

 Housewife

1 (1.6)

9 (4.2)

0.39 (0.05,3.2)

 

 No employment/other

6 (9.8)

10 (4.7)

2.13 (0.7, 6.1)

 

Highest education level

 Never attended school

18 (29.5)

60 (28.3)

Reference

0.96

 Primary

40 (65.6)

139 (65.5)

0.95 (0.5, 1.8)

 

 Secondary

3 (4.9)

12 (5.7)

0.83 (0.2, 3.2)

 

 Vocational college/Tertiary

0 (0)

1 (0.5)

–

 

Social economic status

 Lowest

15 (24.6)

43 (20.3)

Reference

0.03

 Low

22 (36.0)

42 (19.8)

1.50 (0.6, 3.3)

 

 Middle

10 (16.4)

43 (20.3)

0.67 (0.3, 1.6)

 

 High

4 (6.6)

44 (20.7)

0.26 (0.1, 0.8)

 

 Highest

10 (16.4)

40 (18.9)

0.71 (0.3, 1.8)

 

Alcohol drinking

 Never

31 (51.7)

77 (36.3)

Reference

0.06

 Past

26 (43.3)

107 (50.5)

0.60 (0.3, 1.1)

 

 Current

3 (5.0)

28 (13.2)

0.27 (0.1, 0.9)

 

Smoking status

 Never

45 (73.8)

152 (71.7)

Reference

0.92

 Past

14 (22.9)

51 (24.1)

0.93 (0.5, 1.8)

 

 Current

2 (3.3)

9 (4.2)

0.75 (0.2, 3.6)

 

Fruits and vegetables intake per day

 1–2 servings

26 (42.6)

55 (25.9)

Reference

0.04

 3–4 servings

15 (24.6)

64 (30.2)

0.49 (0.2, 1.0)

 

  ≥ 5 servings

20 (32.8)

93 (43.9)

0.45 (0.2, 0.9)

 

Time spent in vigorous physical activity per week (minutes)

 Inadequate (<75 min)

13 (21.3)

51 (24.1)

Reference

0.66

 Adequate (≥75 min)

48 (78.7)

161 (75.9)

1.17 (0.6, 2.3)

 

Months on ARTc

30 (4.5)

31 (5.2)

0.98 (09, 1.0)

0.57

Current ART regimen

 AZT + 3TC + EFV

9 (15.3)

32 (15.9)

Reference

0.92

 AZT + 3TC + NVP

20 (33.9)

64 (31.8)

1.11 (0.5, 2.7)

 

 TDF + FTC + EFV

14 (23.7)

56 (27.9)

0.89 (0.3, 2.3)

 

 TDF + 3TC + EFV

16 (27.1)

49 (24.4)

1.16 (0.5, 2.9)

 

TB treatment at baseline

 Did not receive TB treatment

52 (85.3)

158 (74.5)

Reference

0.08

 Received TB treatment

9 (14.7)

54 (25.5)

0.50 (0.2, 1.1)

 

TB treatment since baseline

 Did not receive TB treatment

50 (82.0)

146 (68.9)

Reference

0.048

 Received TB treatment

11 (18.0)

66 (31.1)

0.48 (0.2, 0.9)

 

Baseline CD4 count (cells/μL)

127 (104)

127 (98)

0.99 (0.9, 1.0)

0.99

Baseline CRP (Log -transformed)d

3.7 (1.7)

3.7 (1.8)

0.99 (0.8, 1.2)

0.91

Follow-up CRP (Log -transformed)

1.8 (1.6)

1.5 (1.4)

1.16 (0.9, 1.4)

0.14

NUSTART intervention assignment

 Control arm

30 (49.2)

98 (46.2)

Reference

0.68

 Treatment arm

31 (50.8)

114 (53.8)

0.89 (0.5, 1.6)

 

Baseline anthropometrics and body composition

 Waist circumference tertiles

    

  Lower

13 (21.3)

51 (24.1)

Reference

0.18

  Middle

27 (44.3)

67 (31.6)

1.58 (0.7, 3.4)

 

  Upper

21 (34.4)

94 (44.3)

0.87 (0.4, 1.9)

 

Hip circumference tertiles

 Lower

23 (37.7)

45 (21.2)

References

0.03

 Middle

18 (29.5)

68 (32.1)

0.52 (0.3, 1.1)

 

 Upper

20 (32.8)

99 (46.7)

0.39 (0.2, 0.8)

 

Body mass index tertiles

 Lower

16 (26.2)

50 (23.6)

Reference

0.78

 Middle

21 (34.5)

68 (32.1)

0.96 (0.5, 2.0)

 

 Upper

24 (39.3)

94 (44.3)

0.79 (0.4, 1.6)

 

Fat mass index tertilese

 Lower

23 (41.8)

41 (21.2)

Reference

0.007

 Middle

17 (30.9)

66 (34.2)

0.46 (0.2, 0.9)

 

 Upper

15 (27.3)

86 (44.6)

0.31 (0.1, 0.7)

 

Fat-free mass index tertilese

 Lower

18 (32.7)

64 (33.2)

Reference

0.67

 Middle

17 (30.9)

70 (36.2)

0.86 (0.4,1.8)

 

 Upper

20 (36.4)

59 (30.6)

1.21 (0.6, 2.5)

 

Follow-up anthropometrics and body composition

 Waist circumference tertiles

  Lower

32 (52.5)

61 (28.8)

Reference

0.0008

  Middle

20 (32.8)

71 (33.5)

0.53 (0.3, 1.0)

 

  Upper

9 (14.7)

80 (37.7)

0.21 (0.1, 05)

 

Hip circumference tertiles

 Lower

30 (49.2)

62 (29.3)

Reference

0.007

 Middle

20 (32.8)

73 (34.4)

0.56 (0.3, 1.1)

 

 Upper

11 (18.0)

77 (36.3)

0.29 (0.1, 0.6)

 

Body mass index tertiles

 Lower

30 (49.2)

61 (28.8)

Reference

0.009

 Middle

18 (29.5)

73 (34.4)

0.50 (0.3, 0.9)

 

 Upper

13 (21.3)

78 (36.8)

0.34 (0.2, 0.7)

 

Fat mass index tertilesf

 Lower

33 (55.0)

57 (27.3)

Reference

0.0003

 Middle

17 (28.3)

73 (34.9)

0.40 (0.2, 0.8)

 

 Upper

10 (16.7)

79 (38.7)

0.21 (0.1, 0.5)

 

Fat-free mass index tertilesf

 Lower

26 (43.3)

64 (30.6)

Reference

 

 Middle

13 (21.7)

77 (36.8)

0.41 (0.2, 0.9)

0.07

 Upper

21 (35.0)

68 (32.6)

0.76 (0.4, 1.5)

 
  1. ART antiretroviral therapy, AZT, Zidovudine, 3TC Lamivudine, EFV Efavirenz, NVP, Nevirapine, TDF Tenofovir, FTC Emtricitabine
  2. aPatients with Pre-diabetes and diabetes
  3. bPatients without pre-diabetes and diabetes
  4. cPD/DM+ patients were 58 and PD/DM- patients were 194
  5. dPD/DM+ patients were 53 and PD/DM- patients were 193
  6. ePD/DM+ patients were 53 and PD/DM- patients were 193
  7. fPD/DM+ patients were 60 and PD/DM- patients were 209